Canadian Cancer Trials Group Bulletins


Single-Study Centres and DSMC Summary Reports

Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.

Trials currently under CCTG's DSMC oversight include:
  • MA.32 - A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
  • BL.12 - A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing On or After a Platinum-Containing Regimen
  • BR.31 - A phase III prospective double-blind placebo-controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer
  • CO.21 - A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (Challenge)
  • CX.5 - A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer
  • HE.1 - Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases
  • IND.213 - A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer
  • IND.219 - A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
  • LY.17 - A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
  • SC.24 - A Phase II Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases
  • MAP.3 - A phase III randomized study of exemestane versus placebo in postmenopausal women at increased risk of developing breast cancer
Trials removed from DSMC oversight include:
  • MA.17R - A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study)
  • CE.6 - A Randomized Phase III Study of Temozolomide and Short-Course Radiation vs. Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
  • CO.23 - A Phase III Randomized Study of BBI608 and Best Supportive Care versus Placebo and Best Supportive Care in Patients with Pretreated Advanced Colorectal Carcinoma
  • OV.21 - A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy
  • IND.209 - A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer
  • IND.210 - A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients with Metastatic Colorectal Cancer
  • IND.211 - A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy